A clinical trial to study the effects of two drugs, neostigmine and dexmedetomidine used in combination with bupivacaine in spinal anaesthesia for lower abdominal surgeries.

"A COMPARATIVE STUDY OF INTRATHECAL NEOSTIGMINE AND DEXMEDETOMIDINE AS ADJUVANT TO 0.5% HYPERBARIC BUPIVACAINE IN SPINAL ANAESTHESIA FOR ELECTIVE LOWER ABDOMINAL SURGERIES" - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055907

Enrollment

Registered

2023-07-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N998- Other intraoperative and postprocedural complications and disorders of genitourinary system

Interventions

Intervention1: Neostigmine : Intrathecal administration of single dose of 50 microgram of Neostigmine as adjuvant to 15 milligram of 0.5% hyperbaric Bupivacaine in spinal anaesthesia for elective lowe

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age group: 18 to 60 years. 2. ASA physical status 1 and 2. 3. Posted for elective lower abdominal surgeries. 4. Informed and written consent will be taken.

Exclusion criteria

Exclusion criteria: 1. Allergy to study drugs. 2. Infection at the site of subarachnoid block. 3. Patient with known coagulopathy or patients on anticoagulation therapy. 4. Patient with any mass lesion in abdomen including pregnancy. 5. Patient with history of neurological disorders. 6. Patient with any contraindications to spinal anaesthesia. 7. Patient with morbid obesity.( >-35 kg/m2).

Design outcomes

Primary

Measure	Time frame
To compare the duration of analgesia in each group.Timepoint: we record analgesic history intra & post operative within 24 hours. Characteristic of pain monitored with Numerical Rating Scale.	—

Secondary

Measure	Time frame
To compare the haemodynamic parametersTimepoint: 24 hours;To compare the onset of motor block in each groupTimepoint: 20 minutes;To compare the onset of sensory block in each group. Timepoint: 20 minutes;To evaluate untoward side effects. Timepoint: 24 hours	—

Countries

India

Contacts

Public ContactDr Nayana Dey

Gauhati Medical College and Hospital

drbandana.mahanta1964@gmail.com7399063633

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026